Welcome to our dedicated page for Immunoprecise news (Ticker: IPA), a resource for investors and traders seeking the latest updates and insights on Immunoprecise stock.
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd. (IPA), reports developments in Bio-Native AI, biologics discovery, and AI-driven drug development. Company updates focus on the HYFT® technology stack and the LensAI™ platform, which combine computational analysis with wet-lab validation for epitope mapping, de novo molecular design, in silico vaccine exploration, immunogenicity screening, and population-scale biologics analytics.
Recurring news also covers earnings releases, platform commercialization, partnership and customer activity, and portfolio initiatives such as B Cell Llama™ nanobody discovery and dengue vaccine research. Corporate updates include the transition from the ImmunoPrecise brand to MindWalk, the Nasdaq ticker change to HYFT, and portfolio refinements such as the divestiture of the Netherlands antibody-discovery operations.
InterVenn Biosciences (NASDAQ: IPA) appointed industry leaders Alec Ford and Mitch Levine to its Board of Directors as it advances commercialization of glycoproteomic diagnostics.
Ford brings 30+ years of genomics and pharma experience, while Levine contributes deep finance and diagnostics leadership across multiple life science companies.
MindWalk Holdings (NASDAQ: HYFT) reported that over 20 drug candidates in partner pipelines originated from its antibody discovery work, with 10 programs now in active Phase 1–3 clinical trials across oncology, immunology, neurology, and infectious disease.
The company highlighted its HYFT® and LensAI™ biological intelligence infrastructure, built on a Knowledge Graph indexing 660 million biological patterns and 25 billion relationships, and a record of 400+ peer-reviewed publications and patents supporting collaborations with firms such as Annexon, argenx, Xencor, Cullinan Oncology, and others.
MindWalk (NASDAQ: HYFT), a bio-native AI company focused on TechBio and drug discovery, will release its Q1 FY2026 financial results on September 15, 2025. The company will host a conference call and webcast at 10:30 AM ET to discuss quarterly results and business highlights.
The earnings call will include a management presentation followed by a Q&A session. Participants can join via phone using various dial-in numbers (US/International: +1-646-307-1963, Toll-free: 800-715-9871) with Conference ID 3224490, or through the webcast link available on the company's IR website.
ImmunoPrecise Antibodies (NASDAQ: IPA) announced its rebranding to MindWalk and a ticker symbol change to HYFT, marking its transformation into a Bio-Native AI platform company. The rebranding unifies ImmunoPrecise Antibodies, BioStrand, and Talem subsidiaries under a single corporate identity.
The company is evolving from a specialized wet-lab services provider to an integrated platform business powered by its LensAI™ platform with HYFT® technology. This transformation enables MindWalk to offer Data-as-a-Service (DaaS) and Software-as-a-Service (SaaS) solutions while expanding into asset generation and large-scale partnerships across the pharmaceutical industry.
ImmunoPrecise Antibodies (NASDAQ: IPA) announced its participation in the upcoming 27th Annual H.C. Wainwright Global Investment Conference, scheduled for September 8-10th, 2025, in New York. Dr. Jennifer Bath, the company's President and CEO, will deliver a corporate presentation and be available for one-on-one meetings with investors throughout the event.
Interested investors can schedule meetings with IPA's management team through their H.C. Wainwright representative or by emailing meetings@hcwco.com.
ImmunoPrecise Antibodies (NASDAQ: IPA) has reached a significant milestone in its universal dengue vaccine development program. Following the June discovery of a unique conserved dengue epitope using their LENSai™ platform with HYFT® technology, the company is advancing to preclinical manufacturing for in vivo testing.
The company will conduct immunization studies in rabbit models at their Canadian facility to evaluate the vaccine candidate's ability to generate monoclonal antibody responses. This progression demonstrates IPA's end-to-end capabilities, combining AI-driven discovery with wet-lab validation. The platform's approach aligns with FDA's encouragement of predictive, human-relevant methods that reduce animal testing reliance.
ImmunoPrecise Antibodies (NASDAQ: IPA) has announced the sale of its Netherlands subsidiary, IPA Europe, to AVS Bio for $12 million USD, generating net proceeds of $11.7 million USD on a cash-free, debt-free basis.
The strategic divestment allows IPA to streamline operations and focus resources on its AI-based Software as a Service (SaaS) platform, LENSai™, powered by HYFT® multi-omics technology. The transaction includes a 12-month Transition Services Agreement to ensure operational continuity.
The proceeds will be used to invest in scientific platforms, data-driven discovery technologies, and expansion of key strategic programs, reinforcing IPA's commitment to accelerating biologics discovery through AI innovation.
AVS Bio, a portfolio company of Arlington Capital Partners, has acquired ImmunoPrecise Antibodies Europe (IPA Europe) from ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA). The acquisition strengthens AVS Bio's European presence and expands its capabilities in antibody discovery, protein expression, and organoid growth factor development.
IPA Europe, with facilities in Utrecht and Oss, Netherlands, provides comprehensive antibody discovery and characterization services, featuring advanced hybridoma and B-cell screening platforms. The company will maintain its existing management structure while operating as a strategic European hub within AVS Bio's network, serving pharmaceutical customers in both human and animal health markets.
ImmunoPrecise Antibodies (NASDAQ: IPA), a bio-native AI company, reported its fiscal year 2025 results with notable achievements. The company delivered record Q4 revenue of $7.0M and its best-ever quarterly Adjusted EBITDA of ($0.3M). Full-year revenue reached $24.5M, with gross margin expanding to 55% from 49% year-over-year.
The company's BioStrand segment grew over 180% in FY2025, now representing over 5% of total revenue with margins approaching 90%. IPA secured a strategic USD $8-10M partnership for antibody-drug conjugates development and demonstrated successful results with its LENSai platform, including breakthrough findings in dengue virus research and GLP-1 peptides development.
The company is strategically realigning to focus on AI-based product development and plans to complete the divestiture of its Dutch subsidiary to streamline operations.
ImmunoPrecise Antibodies (NASDAQ: IPA) has announced expanded study results for its LENSai™ Immunogenicity Screening technology, demonstrating its ability to predict Anti-Drug-Antibody (ADA) risk in therapeutic proteins before clinical trials. The study analyzed 217 marketed and clinical-stage antibodies, achieving a powerful discriminative capability with AUC=0.92.
The technology addresses a critical industry challenge, as up to 40% of biologics fail in late development due to ADA-related issues, resulting in potential losses of $1-2 billion per biologic. LENSai's HYFT-powered screening can evaluate nearly 900 HLA variants in one overnight run, offering significant time and cost advantages over traditional methods.